Zachary Sonenshine

Cooley advised Reverence Capital Partners’ portfolio company Transact Campus, an innovative campus technology and payment solutions company, on a definitive agreement signed by Reverence Capital Partners to sell Transact to Roper Technologies for $1.6 billion.

Cooley advised Milestone Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, on its refreshment of its board of directors and cooperation agreement with Alta Fundamental Advisers.

Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.

Cooley advised Lantheus Holdings, a top publicly traded radiopharmaceutical-focused company, on a concurrent private investment in public equity (PIPE) transaction, partnering transaction and asset sale with Perspective Therapeutics.

Cooley advised Nutrafol, a leading provider of hair wellness products, on its agreement to sell a majority stake in the company to Unilever. Partner Kevin Cooper led the Cooley team advising Nutrafol on the transaction, and partner Stephane Levy has acted as longtime corporate counsel to the company. Nutrafol is backed by Unilever Ventures and consumer-focused private equity firm L Catterton.